Dr. Hansen on the Promise of ALLO-715 in Relapsed/Refractory Multiple Myeloma
In Partnership With:
Doris Hansen, MD, discusses the promise of ALLO-715 in relapsed/refractory multiple myeloma. Scroll to 0:07 in the video for Dr. Hansen's topline points on the agent.
Doris Hansen, MD, assistant member, Moffitt Cancer Center, Department of Blood and Marrow Transplant and Cellular Immunotherapy, discusses the promise of ALLO-715 in relapsed/refractory multiple myeloma.
ALLO-715 is a novel CAR T-cell therapy directed toward BCMA. Unlike autologous CAR T-cell therapies, ALLO-715 is an allogeneic, off-the-shelf product that has the potential to mitigate manufacturing challenges encountered with the autologous approach, Hansen explains.
Furthermore, many patients with relapsed/refractory multiple myeloma experience disease progression during the period required for autologous CAR T-cell therapy generation. With ALLO-715, patients can receive their infusion within a period of 5 days, Hansen says.
Initial findings from the ongoing phase 1 UNIVERSAL trial (NCT04093596) demonstrated an overall response rate of 60% with a 320 x 106 dose of CAR cells in 6 patients with relapsed/refractory multiple myeloma. Four patients treated at this dose level achieved at least a very good partial response and minimal residual disease negativity.
On April 21, 2021, the FDA granted ALLO-715 a Regenerative Medicine Advanced Therapy designation as a potential treatment for patients with relapsed/refractory multiple myeloma.
